piko-1口袋式肺活量计检测的准确性
2012/02/29
背景：哮喘长期治疗的主要目的是获得好的哮喘控制。基于全球哮喘倡议（GINA）指南(www.ginasthma.com)，医学专家根据哮喘相关症状和肺活量检测时的第一秒用力呼气体积（FEV1）来评价哮喘控制。接受过哮喘发作早期自我监测的患者，采用以症状为基础的问卷调查（如哮喘控制测试[ACT]）来评价哮喘控制。然而，一些患者则倾向于采用硬指标，如呼气流速峰值等，来进行哮喘自我管理。
目的：与记录呼气流速峰值相比，家庭监测FEV1可能更有价值。廉价、口袋式手持肺活量计Piko-1®可用于监测和连续储存FEV1值。本试验旨在评价Piko-1®检测FEV1的准确性。
方法：20名自愿者采用20台Piko-1®连续5天检测。所有结果与校正后的参考肺活量计检测的每日FEV1进行比较。
结果：总体来说，虽然Piko-1对于FEV1下限值估计不足，但准确性尚可接受。此外，不同Piko-1肺活量计检测的结果也未出现明显的异质性。
结论： Piko-1能准确检测FEV1，可在临床试验中比较用Piko-1检测的结果评价哮喘发作和单独基于症状评价的哮喘发作。
目的：与记录呼气流速峰值相比，家庭监测FEV1可能更有价值。廉价、口袋式手持肺活量计Piko-1®可用于监测和连续储存FEV1值。本试验旨在评价Piko-1®检测FEV1的准确性。
方法：20名自愿者采用20台Piko-1®连续5天检测。所有结果与校正后的参考肺活量计检测的每日FEV1进行比较。
结果：总体来说，虽然Piko-1对于FEV1下限值估计不足，但准确性尚可接受。此外，不同Piko-1肺活量计检测的结果也未出现明显的异质性。
结论： Piko-1能准确检测FEV1，可在临床试验中比较用Piko-1检测的结果评价哮喘发作和单独基于症状评价的哮喘发作。
（苏楠 审校）
J Asthma. 2012 Feb;49(1):45-50. Epub 2011 Dec 28.
J Asthma. 2012 Feb;49(1):45-50. Epub 2011 Dec 28.
Source
Department of Internal Medicine and Pneumology, Zürcher Höhenklinik Davos , Davos Clavadel, Switzerland.
Department of Internal Medicine and Pneumology, Zürcher Höhenklinik Davos , Davos Clavadel, Switzerland.
Abstract
BACKGROUND：Good asthma control is the main goal of long-term asthma treatment. According to the Global Initiative for Asthma (GINA) guidelines (www.ginasthma.com), medical professionals assess asthma control based on specific questions regarding asthma symptoms and by spirometry measuring forced expiratory volume in 1 second (FEV(1)). Patients trained in early self-detection of asthma exacerbations use a symptom-based questionnaire, such as the Asthma Control Test (ACT) [Nathan RA, Sorkness CA, Kosinski M, et al. Development of the Asthma Control Test. A survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-64]. However, some patients may prefer harder indicators, like peak flow values, when considering how to act within their regular asthma self-management plan.
OBJECTIVES：Monitoring of FEV(1) at home could be an even more valuable alternative to recording peak flow values. The inexpensive handheld pocket spirometer "Piko-1®" offers the opportunity to monitor and store consecutive FEV(1) values. This study assesses the accuracy of the Piko-1 device.
METHODS：Twenty volunteers tested 20 Piko-1 devices over five consecutive days. All results were compared to daily FEV(1) values, as measured by a calibrated reference spirometer.
RESULTS：Overall, the accuracy was acceptable, although Piko-1 tended to underestimate FEV(1) in the lower range. Moreover, there was no evidence of major heterogeneity between Piko-1 devices.
CONCLUSION：The Piko-1 FEV(1) measurements are sufficiently accurate to start a clinical trial to compare the detection of asthma exacerbations with this device and based on asthma symptoms alone.
BACKGROUND：Good asthma control is the main goal of long-term asthma treatment. According to the Global Initiative for Asthma (GINA) guidelines (www.ginasthma.com), medical professionals assess asthma control based on specific questions regarding asthma symptoms and by spirometry measuring forced expiratory volume in 1 second (FEV(1)). Patients trained in early self-detection of asthma exacerbations use a symptom-based questionnaire, such as the Asthma Control Test (ACT) [Nathan RA, Sorkness CA, Kosinski M, et al. Development of the Asthma Control Test. A survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-64]. However, some patients may prefer harder indicators, like peak flow values, when considering how to act within their regular asthma self-management plan.
OBJECTIVES：Monitoring of FEV(1) at home could be an even more valuable alternative to recording peak flow values. The inexpensive handheld pocket spirometer "Piko-1®" offers the opportunity to monitor and store consecutive FEV(1) values. This study assesses the accuracy of the Piko-1 device.
METHODS：Twenty volunteers tested 20 Piko-1 devices over five consecutive days. All results were compared to daily FEV(1) values, as measured by a calibrated reference spirometer.
RESULTS：Overall, the accuracy was acceptable, although Piko-1 tended to underestimate FEV(1) in the lower range. Moreover, there was no evidence of major heterogeneity between Piko-1 devices.
CONCLUSION：The Piko-1 FEV(1) measurements are sufficiently accurate to start a clinical trial to compare the detection of asthma exacerbations with this device and based on asthma symptoms alone.
J Asthma. 2012 Feb;49(1):45-50. Epub 2011 Dec 28.
上一篇：
儿童哮喘健康转归检测的特征
下一篇：
重度哮喘患者血清IgE浓度存在临床显著性变异
